Feed

VKTX

Viking Therapeutics

VKTX · NASDAQ

$32.13 -1.14% (-$0.37)

1M -5.56%

Market Cap $3.75B

P/E Ratio -

Div. Yield -

ROE 94.56%

Bulios Fair Price

$23.2

27.8% downside

Current Price

$32.13

Undervalued Fair Value Overvalued

According to Bulios Fair Price, VKTX is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak

1/9

Valuation

0 /100

Expensive

P/B 9.18x

P/FCF N/A

P/S N/A

Growth

100 /100

Growing

Book val. growth 63.83%

Rev. growth N/A

FCF growth N/A

Profitability

N/A

FCF margin N/A

Op. margin N/A

Gross margin N/A

Quality

0 /100

Poor

Asset turnover 0.00x

ROA 102.47%

ROIC 135.80%

Debt

69 /100

Low

Current ratio 4.72x

Int. coverage -66,848.50x

Debt/Equity 0.01x

Stability

37 /100

Moderate

EPS volatility 120.52%

Profitable years 0

Beta 0.68x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about VKTX

Online

About the company

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Sector

Healthcare

Industry

Biotechnology

CEO

Brian Lian

Employees

Headquarters

San Diego

Upcoming events

28 OCT

Earnings

Upcoming earnings report

47d

⌘ K

StockBot Live

Market situation Wall Street

Wall Street slides as surging oil fuels rate fears

S&P 500 -0.58% and Nasdaq -0.65% drop as surging oil fuels rate hike fears. Europe's DAX +0.66% holds firm.

Ask about this

StockBot knows 80,000+ stocks worldwide